Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.18
NVSEF's Cash to Debt is ranked lower than
88% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. NVSEF: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
NVSEF' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.23 Max: N/A
Current: 0.18
Equity to Asset 0.54
NVSEF's Equity to Asset is ranked lower than
62% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVSEF: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
NVSEF' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.54
0.51
0.65
Interest Coverage 12.80
NVSEF's Interest Coverage is ranked lower than
60% of the 468 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.86 vs. NVSEF: 12.80 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s Interest Coverage Range Over the Past 10 Years
Min: 13.42  Med: 16.32 Max: 30.91
Current: 12.8
13.42
30.91
F-Score: 4
Z-Score: 2.43
M-Score: -2.70
WACC vs ROIC
7.24%
7.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.27
NVSEF's Operating margin (%) is ranked higher than
78% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. NVSEF: 17.27 )
Ranked among companies with meaningful Operating margin (%) only.
NVSEF' s Operating margin (%) Range Over the Past 10 Years
Min: 17.41  Med: 20.34 Max: 22.35
Current: 17.27
17.41
22.35
Net-margin (%) 13.55
NVSEF's Net-margin (%) is ranked higher than
76% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. NVSEF: 13.55 )
Ranked among companies with meaningful Net-margin (%) only.
NVSEF' s Net-margin (%) Range Over the Past 10 Years
Min: 15.35  Med: 19.02 Max: 35.29
Current: 13.55
15.35
35.29
ROE (%) 8.88
NVSEF's ROE (%) is ranked higher than
58% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. NVSEF: 8.88 )
Ranked among companies with meaningful ROE (%) only.
NVSEF' s ROE (%) Range Over the Past 10 Years
Min: 12.6  Med: 15.32 Max: 25.73
Current: 8.88
12.6
25.73
ROA (%) 5.06
NVSEF's ROA (%) is ranked higher than
58% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. NVSEF: 5.06 )
Ranked among companies with meaningful ROA (%) only.
NVSEF' s ROA (%) Range Over the Past 10 Years
Min: 7.21  Med: 8.97 Max: 16.18
Current: 5.06
7.21
16.18
ROC (Joel Greenblatt) (%) 48.46
NVSEF's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. NVSEF: 48.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVSEF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 39.09  Med: 59.49 Max: 69.76
Current: 48.46
39.09
69.76
Revenue Growth (3Y)(%) -1.30
NVSEF's Revenue Growth (3Y)(%) is ranked lower than
70% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVSEF: -1.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVSEF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.1  Med: 4.70 Max: 75.8
Current: -1.3
-2.1
75.8
EBITDA Growth (3Y)(%) -6.80
NVSEF's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. NVSEF: -6.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVSEF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 5.40 Max: 81.6
Current: -6.8
-10.5
81.6
EPS Growth (3Y)(%) -7.20
NVSEF's EPS Growth (3Y)(%) is ranked lower than
70% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVSEF: -7.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVSEF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.2  Med: 5.90 Max: 83.5
Current: -7.2
-7.2
83.5
» NVSEF's 10-Y Financials

Financials (Next Earnings Date: 2016-07-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:MRK, NYSE:BMY, OTCPK:GLAXF, NYSE:SNY, NYSE:ABBV, NYSE:LLY, OTCPK:BAYRY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:OPHLY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, NAS:ZSPH » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVS.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.

Ratios

vs
industry
vs
history
P/E(ttm) 29.47
NVSEF's P/E(ttm) is ranked lower than
52% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.34 vs. NVSEF: 29.47 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.79 Max: 29.47
Current: 29.47
5.7
29.47
Forward P/E 17.04
NVSEF's Forward P/E is ranked lower than
52% of the 65 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. NVSEF: 17.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.80
NVSEF's PE(NRI) is ranked lower than
53% of the 533 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.24 vs. NVSEF: 29.80 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.10 Max: 31.15
Current: 29.8
10.63
31.15
Price/Owner Earnings (ttm) 18.00
NVSEF's Price/Owner Earnings (ttm) is ranked higher than
76% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.00 vs. NVSEF: 18.00 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVSEF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.71 Max: 23.92
Current: 18
7.18
23.92
P/B 2.71
NVSEF's P/B is ranked higher than
55% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. NVSEF: 2.71 )
Ranked among companies with meaningful P/B only.
NVSEF' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.48 Max: 4.14
Current: 2.71
1.69
4.14
P/S 4.00
NVSEF's P/S is ranked lower than
62% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. NVSEF: 4.00 )
Ranked among companies with meaningful P/S only.
NVSEF' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 3.26 Max: 5.01
Current: 4
1.88
5.01
PFCF 24.23
NVSEF's PFCF is ranked higher than
51% of the 189 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.95 vs. NVSEF: 24.23 )
Ranked among companies with meaningful PFCF only.
NVSEF' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 16.80 Max: 26.84
Current: 24.23
7.05
26.84
POCF 17.03
NVSEF's POCF is ranked higher than
53% of the 254 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.49 vs. NVSEF: 17.03 )
Ranked among companies with meaningful POCF only.
NVSEF' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.05 Max: 19.4
Current: 17.03
5.77
19.4
EV-to-EBIT 26.51
NVSEF's EV-to-EBIT is ranked lower than
63% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.96 vs. NVSEF: 26.51 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.50 Max: 26.8
Current: 26.51
8.5
26.8
EV-to-EBITDA 17.72
NVSEF's EV-to-EBITDA is ranked lower than
51% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.28 vs. NVSEF: 17.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.10 Max: 18.1
Current: 17.72
7.3
18.1
Shiller P/E 16.29
NVSEF's Shiller P/E is ranked higher than
86% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.12 vs. NVSEF: 16.29 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s Shiller P/E Range Over the Past 10 Years
Min: 9.66  Med: 14.22 Max: 21.52
Current: 16.29
9.66
21.52
Current Ratio 0.83
NVSEF's Current Ratio is ranked lower than
92% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NVSEF: 0.83 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.40 Max: 2.83
Current: 0.83
0.83
2.83
Quick Ratio 0.59
NVSEF's Quick Ratio is ranked lower than
93% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. NVSEF: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.15 Max: 2.48
Current: 0.59
0.59
2.48
Days Inventory 133.94
NVSEF's Days Inventory is ranked lower than
61% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. NVSEF: 133.94 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 142.51 Max: 183.42
Current: 133.94
117.85
183.42
Days Sales Outstanding 62.50
NVSEF's Days Sales Outstanding is ranked higher than
60% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. NVSEF: 62.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 62.36 Max: 69.89
Current: 62.5
56.31
69.89
Days Payable 98.46
NVSEF's Days Payable is ranked higher than
68% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. NVSEF: 98.46 )
Ranked among companies with meaningful Days Payable only.
NVSEF' s Days Payable Range Over the Past 10 Years
Min: 88.14  Med: 111.44 Max: 120.63
Current: 98.46
88.14
120.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.33
NVSEF's Dividend Yield is ranked higher than
88% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. NVSEF: 3.33 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.27 Max: 5.11
Current: 3.33
1.47
5.11
Dividend Payout 0.97
NVSEF's Dividend Payout is ranked higher than
63% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. NVSEF: 0.97 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s Dividend Payout Range Over the Past 10 Years
Min: 1.12  Med: 1.67 Max: 3.22
Current: 0.97
1.12
3.22
Dividend Growth (3y) 5.40
NVSEF's Dividend Growth (3y) is ranked lower than
54% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. NVSEF: 5.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVSEF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.80 Max: 18.5
Current: 5.4
0
18.5
Forward Dividend Yield 3.33
NVSEF's Forward Dividend Yield is ranked higher than
82% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVSEF: 3.33 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.65
NVSEF's Yield on cost (5-Year) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. NVSEF: 4.65 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.05  Med: 4.56 Max: 7.13
Current: 4.65
2.05
7.13
3-Year Average Share Buyback Ratio 0.60
NVSEF's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 424 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. NVSEF: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVSEF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -224.6  Med: 0.10 Max: 2.3
Current: 0.6
-224.6
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 32.70
NVSEF's Price/Tangible Book is ranked lower than
97% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NVSEF: 32.70 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.16  Med: 4.26 Max: 12455
Current: 32.7
0.16
12455
Price/Projected FCF 1.29
NVSEF's Price/Projected FCF is ranked higher than
78% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. NVSEF: 1.29 )
Ranked among companies with meaningful Price/Projected FCF only.
NVSEF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.09 Max: 2.52
Current: 1.29
0.65
2.52
Price/Median PS Value 1.23
NVSEF's Price/Median PS Value is ranked lower than
56% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. NVSEF: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.14 Max: 3.11
Current: 1.23
0.64
3.11
Price/Graham Number 6.58
NVSEF's Price/Graham Number is ranked lower than
89% of the 409 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. NVSEF: 6.58 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.96 Max: 81.67
Current: 6.58
0.43
81.67
Earnings Yield (Greenblatt) (%) 3.80
NVSEF's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVSEF: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVSEF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.50 Max: 11.8
Current: 3.8
3.7
11.8
Forward Rate of Return (Yacktman) (%) 2.95
NVSEF's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.89 vs. NVSEF: 2.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVSEF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 14.20 Max: 69.3
Current: 2.95
1
69.3

More Statistics

Revenue (TTM) (Mil) $49,995
EPS (TTM) $ 2.81
Beta0.71
Short Percentage of Float0.00%
52-Week Range $71.00 - 106.53
Shares Outstanding (Mil)2,381.28

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 48,982 50,424 55,501
EPS ($) 4.87 5.08 6.14
EPS w/o NRI ($) 4.87 5.08 6.14
EPS Growth Rate
(3Y to 5Y Estimate)
3.16%
» More Articles for OTCPK:NVSEF

Headlines

Articles On GuruFocus.com
Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies Jun 13 2016 
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Valeant's Share Price Continues to Decline Feb 05 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
Guru Stocks at 52-Week Lows Jan 26 2016 
Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 

More From Other Websites
What Are the Benefits of the Novartis-Xencor Alliance to Xencor? Jul 01 2016
How Could the Novartis-Xencor Alliance Benefit Novartis? Jul 01 2016
Cramer: This stock's overreaction could trigger a comeback Jun 30 2016
The Novartis-Xencor Collaboration Agreement: The Details Jun 30 2016
These 5 Big Stocks Are Breaking Out This Summer Jun 30 2016
Xencor Stock Up On Cancer Drugs Partnership with Novartis Jun 29 2016
Inside the CHMP’s Refusal of Novartis’s Arzerra as a Maintenance Treatment Jun 29 2016
5 Wide-Moat Stocks Now Selling at a Discount Jun 29 2016
Xencor signs cancer-drug deal with Novartis; its stock surges 32% Jun 28 2016
Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer Jun 28 2016
Novartis AG breached its 50 day moving average in a Bearish Manner : NVSEF-US : June 28, 2016 Jun 28 2016
Novartis and Xencor enter into bispecific antibody agreement Jun 28 2016
Novartis AG – Value Analysis (US OTC:NVSEF) : June 20, 2016 Jun 20 2016
CORRECTED (OFFICIAL)-Novartis aims to nearly triple biosimilar drugs on market by 2020 Jun 20 2016
Novartis aims to nearly triple biosimilar drugs on market by 2020 Jun 19 2016
Roche skin cancer drugs "too expensive", says UK cost agency Jun 16 2016
Novartis AG breached its 50 day moving average in a Bearish Manner : NVSEF-US : June 14, 2016 Jun 14 2016
Colombia Makes Good On Its Threat Against Novartis AG (NVS) Jun 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)